45308302.der.pdf

• filename: 45308302.der.pdf
• MRIDs: 45308302
• CHEMICAL_SUBSTANCE_NAME: Scopolamine hydrobromide
• CHEMICAL_CASRN: 114-49-8
• CHEMICAL_PC_CODE: 600094
• STUDY_CITATION: Myers, D. (2000) Assessment of the Effect of Scopolamine on Auditory Startle Response and Morris Water Maze Learning in Young Rats Positive Control Study: Lab Project Number: HLS059/002438. Unpublished study prepared by Huntingdon Life Sciences Ltd. 75 p.
• STUDY_YEAR: 2000.0
• EXECUTIVE_SUMMARY: Scopolamine hydrobromide: As part of a series of studies submitted to demonstrate the proficiency of Huntingdon Life Sciences, Ltd., Cambridgeshire, England to perform neurotoxicology and neuropathology tests on male and female CD (Sprague Dawley) rats, auditory startle response habituation, prepulse inhibition of startle and Morris water maze learning and memory (MRID 45308302) were assessed in groups of 10-11 rats/sex. Scopolamine (Lot # 47H0635) was administered at a dosage of 1.5 mg/kg/day by intraperitoneal injection on postnatal day (PND) 26±2 and PND 28±2, or on PND 63±3; controls received 0.9% saline vehicle only. Animals were tested in the Morris water maze 20 minutes after dosing; for startle response, animals were tested immediately following dosing. Animals were tested for startle response habituation and prepulse inhibition at PND 26±2 and in the Morris water maze at PND 28±2; the same animals were used each day. Animals treated at PND 63±3 were tested for startle response habituation and Morris maze performance. Clinical signs, body weight, and necropsy findings were not reported. Scopolamine treatment at PND 28 and 63 was associated with a general impairment of performance in the Morris water maze. In both sexes at each age, there were some statistically significant increases in mean trial time and mean sectors entered compared with controls. Control females showed auditory startle habituation on PNDs 26 and 63. Scopolamine-treated females showed a significant decrease in the degree of habituation between the first two trial blocks on PND 63, compared with controls. Scopolamine treatment on PND 26 was associated with an impairment of prepulse inhibition, as indicated by a significant decrease in the percentage inhibition of the mean startle amplitude (control males: 56.4%; females: 54.2% versus scopolamine males: 34.2%; females: 38.2%). This study is classified Acceptable/Nonguideline. Huntingdon Life Sciences, Ltd. has demonstrated proficiency in this study for detecting changes in Morris water maze learning and auditory startle response tests due to Scopolamine treatment in postweaning and young adult CD (Sprague Dawley) rats (PND 26-63) for the time period around 1998 (in life period of study). This positive control study does not satisfy any guideline requirement.
• STUDY_TYPE: Other
• GUIDELINE_COMMENT: NA [81-9, Developmental neurotoxicity (use 870.3650 or 870.6300 instead of this)]
• ADMIN_ROUTE: Intraperitoneal
• DOSE_PERIOD: No Duration Period; Neurobehavioral (auditory startle response and learning and memory) positive control data
• txr: 53777.0
• memoDate: 2012-03-20
• UpdateDate: 2016-09-07
• Comments:

• md5: e57107649bf58786a58ab5dd02c9857f
• sha1: 0959ece281dd39ba4ff94486138c63281dbc3e50
• sha224: 6866eacac84203bfedc149c5627e990fae54d7ec9f71cf7e54a9586c
• sha256: c30e9c731ca0d08725d7e6bf1e9bde080b3945a658df4ff6ae33f57ee8a30c31
• sha384: 73490a15816ccd59ce1775464a237922ac90139bb6b023078403efd29567e886a47635a4862338e4b97c12197149b13f
• sha512: 990889c6135a6a20d7bd493f20e3e73398bb4b341adf53ca8b1e8958104ad6d47279ea9d493678dee33512b2c1e3440ac40ba9868fbaddb0ab6d723853f7fc16